ResearcherThe First Affiliated Hospital, Sun Yat-sen UniversityActive in the last 2 years

Xiao‐Yu Yin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5147623229. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/advs.77048 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ying‐Qin Zhu · 1 shared paper, 2026 · strength 0.28
- Paper Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. DOI 10.1002/advs.77048 ↗
De-Liang Fang · 1 shared paper, 2026 · strength 0.28
- Paper Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. DOI 10.1002/advs.77048 ↗
Mingjian Ma · 1 shared paper, 2026 · strength 0.28
- Paper Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. DOI 10.1002/advs.77048 ↗
Zhide Liu · 1 shared paper, 2026 · strength 0.28
- Paper Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. DOI 10.1002/advs.77048 ↗
Siyuan Lu · 1 shared paper, 2026 · strength 0.28
- Paper Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. DOI 10.1002/advs.77048 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.